Drug Store News - Schering-Plough, marketer of high-profile allergy products Claritin and Clarinex, last month decided not to exercise its option agreement related to…
Schering-Plough, marketer of high-profile allergy products Claritin and Clarinex, last month decided not to exercise its option agreement related to ALK-Abello’s grass-pollen allergy tablet and other non-injectable allergy products, the company reported.
ALK-Abello has reacquired the exclusive worldwide. rights to these products, ending the collaboration the two companies entered in October 2002.
Related Results
WALL STREET CHOICE: SCHERING-PLOUGH SHOWS PROMISE
Marlborough, Mass., Firm’s Allergy Drug Is Turned Away by FDA.
Manufacturing Problems Cast Pall on Schering-Plough Earnings.(Statistical Dat…
Tab for Allergy Pills Likely to Rise.
New Jersey Insurers’ Changed Policy on Allergy Drugs Presents New Irritant.
Given that many prescription allergy medications are either switching to OTC or are in danger of being forced OTC, introducing a prescription-only allergy remedy may not be as promising as it once was.
COPYRIGHT 2004 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
